MARK2 and cancer: PIM1 is a serine/threonine kinase, the expression of which is controlled by the JAK/STAT pathway, and has also been associated with resistance to chemotherapy33–35 and molecularly targeted agents36,37 in several cancer types, but to our knowledge not previously for NB.